Clinical trials: Multiple Sclerosis, Chronic Progressive
Progressive Multiple Sclerosis
G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis
The logistic advantages and advanced training capabilities of the G-EO System, as well as the benefits reported in other populations, support this strategy as a potentially potent rehabilitation tool for restoring and maintaining…
- Trial name
- NCT03980145
- Testing
- G-EO System (Reha Technology AG: Olten, Switzerland), Conventional Physical Therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
The purpose of this MAP Cohort Treatment Plan is to allow access to siponimod for eligible patients diagnosed with Secondary Progressive Multiple Sclerosis with active disease.
- Trial name
- NCT04540861
- Testing
- Siponimod
- Sponsor
- Novartis Pharmaceuticals
Autoimmune Diseases of the Nervous System, Multiple Sclerosis
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
The purpose of this study is to determine whether Tcelna (imilecleucel-T, autologous T-Cell Immunotherapy) is effective in the treatment of secondary progressive multiple sclerosis (SPMS).
- Conditions
- Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression
- Trial name
- Abili-T (NCT01684761)
- Testing
- Tcelna
- Where
- 36 sites in United States, Canada
- Volunteers
- 183 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis, Progressive Multiple Sclerosis
Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
The primary objective of the study is to investigate neuroregenerative efficacy (proof of concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological parameters in patients with progressive MS.
- Trial name
- SMART-MS (NCT04749667)
- Testing
- MSCs, Saline
- Where
- 4 sites in Norway
- Volunteers
- 18 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06138132
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Home Based Functional Balance Intervention for Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- HomeFBIinMS (NCT07355387)
- Testing
- Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois at Chicago
Secondary Progressive Multiple Sclerosis
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia.
- Trial name
- EMBOSSES (NCT07168694)
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Pilot Study of Lithium in Progressive Multiple Sclerosis
The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.
- Trial name
- NCT01259388
- Testing
- Lithium Carbonate
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- VA Office of Research and Development
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis
- Trial name
- NCT07006805
- Testing
- CABA-201
- Sponsor
- Cabaletta Bio
Primary Progressive Multiple Sclerosis, Exercise
The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS
Endurance training revealed to be an effective means to increase cardiorespiratory fitness in persons with Multiple Sclerosis (MS), considered relevant to health-related quality of life in this population.
- Conditions
- Primary Progressive Multiple Sclerosis, Exercise, Cardiorespiratory Fitness
- Trial name
- CYPRO (NCT05229861)
- Testing
- HIIT, MCT
- Where
- Switzerland
- Volunteers
- 61 people
- Sponsor
- Klinik Valens
Non-Active Secondary Progressive Multiple Sclerosis
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible…
- Trial name
- TILS-022 (NCT06890923)
- Testing
- Foralumab TZLS-401 100 µg
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Tiziana Life Sciences LTD
Primary Progressive Multiple Sclerosis
Gray Matter Demyelination in Primary Progressive MS at 7T
Progressive-onset multiple sclerosis (PPMS) occurs in about 15% of all people living with MS. PPMS remains understudied, and most disease-modifying treatments are ineffective for PPMS.
- Trial name
- NCT04977622
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Progressive Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the…
- Trial name
- VASOSEP (NCT02580669)
- Testing
- Neuropsychological assessment, Neurologic consultation, MRIs (with vasoreactivity testing)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Cognitive Reserve-building Activities in Multiple Sclerosis
The study is a crossover randomized controlled trial investigating the effect of increasing engagement in cognitive leisure activities for individuals with multiple sclerosis.
- Trial name
- CRAMS (NCT05691192)
- Testing
- Cognitive Leisure Activities
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Progressive Multiple Sclerosis
Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis
The purpose of this study is to determine whether cyclic oral methylprednisolone once every month has an effect on the intrathecal inflammation in patients suffering from progressive multiple sclerosis.
- Trial name
- COMTiMS (NCT01305837)
- Testing
- methylprednisolone
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis, Progressive Multiple Sclerosis
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.
- Trial name
- Norseman (NCT05740722)
- Testing
- Nicotinamid riboside
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Haukeland University Hospital